ArticleBreast cancer (Tokyo, Japan)2026
Characteristics of a multigene assay (MammaPrint/Blueprint) to predict early recurrence of hormone receptor-positive, HER2-negative breast cancer: a case‒control study (WJOG16722B).
Article in Breast cancer (Tokyo, Japan), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHormone receptor-positive, HER2-negative (HR + /HER2-) breast cancer generally has a favorable prognosis; however, early postoperative recurrence markedly reduces survival. Accurate prediction of early recurrence is crucial for personalizing treatment. This case-control study compared MammaPrint (MP) and BluePrint (BP) results between early recurrence patients and matched controls.
methodsPatients were selected from our previous study, the WJOG15721B cohort (n = 2732). Those with recurrence within three years after surgery were randomly extracted, and controls matched for institution, clinical stage, and number of pathological lymph node metastases were included (n = 124). Tumor samples underwent MP and BP assays to classify recurrence risk and molecular subtypes.
resultsOf 115 submitted tumor samples, 85 were analyzed successfully (43 early recurrence, 42 no recurrence). High-risk MP classification was significantly more frequent in early recurrence patients (79.1% vs. 40.5%, p < 0.001), and Luminal B BP subtype was more common in early recurrence patients (79.1% vs. 38.1%, p < 0.001). High MP risk was associated with high Ki-67 levels and higher nuclear grade. Integrating clinical and genomic risk enhanced prognostic precision: patients with both clinical and genomic high risk had the highest recurrence rate (100%), those with low clinical and genomic risk had the lowest (28.1%), and patients with low clinical but high genomic risk showed an intermediate recurrence rate (57.5%).
conclusionsCompared with patients without recurrence, those with early recurrence showed a significantly higher prevalence of high-risk MP results and Luminal B BP subtype. High-risk MP/Luminal B BP subtype suggested an association with early recurrence in patients with HR + /HER2- early breast cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.